论文部分内容阅读
60例口服降糖药血糖控制不良的T2DM患者随机分为甘精组,n=30和预混组,n=30,所有患者以二甲双胍作为基础用药,后血糖控制不良者酌情加用瑞格列奈;预混组每日餐前分别注射2～3次诺和锐30。根据血糖水平调整胰岛素剂量,观察12周。结果:两组治疗后血糖及HbA1c较前明显下降、C肽分泌改善(P<0.01),甘精组空腹血糖下降更明显(P<0.05)、空腹血糖达标时间缩短、低血糖发生率低、胰岛素用量明显减少(P<0.01)并且体重无明显改变(P>0.05)。结论:以二甲双胍为基础治疗措施的T2DM患者联合甘精胰岛素、瑞格列奈治疗可以有效降低血糖,空腹血糖控制更低、更快,对体重影响小,低血糖发生率低。
Sixty T2DM patients with dysglycemic control of oral hypoglycemic agents were randomly divided into Gan Gan group, n = 30 and pre-mixed group, n = 30, all patients with metformin as the basis for medication, post-glycemic control, Chennai; Pre-mixed group were injected daily before meals 2 to 3 times Novo Rui 30. Insulin dose was adjusted according to blood glucose level and observed for 12 weeks. Results: After treatment, blood glucose and HbA1c decreased significantly, C peptide secretion improved (P <0.01), fasting blood glucose decreased more significantly in Gan Ganjing group (P <0.05), shortened fasting blood glucose compliance time, low incidence of hypoglycemia, Insulin consumption was significantly reduced (P <0.01) and no significant change in body weight (P> 0.05). Conclusion: Metformin-based T2DM patients combined with insulin glargine and repaglinide can effectively lower blood glucose, lower and faster fasting blood glucose control, less impact on body weight, and lower incidence of hypoglycemia.